Pharmacogenetics of chronic cardiovascular drugs: Applications and implications

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 11, 2006, Pages 1417-1427

  Zineh, Issam ^a   Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cardiovascular disease; Dislipidaemia; Heart failure; Hypertension; Pharmacogenetics; Pharmacogenomics; Warfarin

Indexed keywords

ADDUCIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARDIOVASCULAR AGENT; CARVEDILOL; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; METOPROLOL; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; WARFARIN;

AMINO ACID SUBSTITUTION; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; GENE EXPRESSION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MORTALITY; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTICOAGULANTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; HYPERTENSION; PHARMACOGENETICS;

EID: 33746806364     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.11.1417     Document Type: Review

References (90)

1. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J. Card. Fail. (1999) 5(4):357-382. Erratum in J. Card. Fail. (2000) 6(1):74.
2. CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42:1206-1252.
3. GRUNDY SM, CLEEMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110(2):227-239.
4. HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation (2001) 104(24):2996-3007.
5. MATERSON BJ: Variability in response to antihypertensive drug treatment. Hypertension (2004) 43(6):1166-1167.
6. MATERSON BJ, REDA DJ, CUSHMAN WC et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. (1993) 328(13):914-921. Erratum in N. Engl. J. Med. (1994) 330(23):1689.
7. PEDRO-BOTET J, SCHAEFER EJ, BAKKER-ARKEMA RG et al.: Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis (2001) 158(1):183-193.
8. DANG MT, HAMBLETON J, KAYSER SR: The influence of ethnicity on warfarin dosage requirement. Ann. Pharmacother. (2005) 39(6):1008-1012.
9. SZCZEKLIK A, MUSIAL J, UNDAS A, SANAK M: Aspirin resistance. J. Thromb. Haemost. (2005) 3(8):1655-1662.
10. JOHNSON JA, ZINEH I, PUCKETT BJ et al.: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. (2003) 74(1):44-52.
11. JOHNSON JA, CAVALLARI LH: Cardiovascular pharmacogenomics. Exp. Physiol. (2005) 90(3):283-289.
12. JOHNSON JA, ZINEH I: Pharmacogenetics and personalized medicine. In Cardiovascular Genetics and Genomics for the Cardiologist. Zhao V (ed.) (In Press).
13. MASON DA, MOORE JD, GREEN SA, LIGGETT SB: A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J. Biol. Chem. (1999) 274(18):12670-12674.
14. LEVIN MC, MARULLO S, MUNTANER O, ANDERSSON B, MAGNUSSON Y: The myocardium-protective g]y-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J. Biol. Chem. (2002) 277(34):30429-30435.
15. RATHZ DA, BROWN KM, KRAMER LA, LIGGETT SB: Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. (2002) 39(2):155-160.
16. KARLSSON J, LIND L, HALLBERG P et al.: Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin. Cardiol. (2004) 27(6):347-350.
17. LIU J, LIU ZQ, TAN ZR et al.: Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin. Pharmacol. Ther. (2003) 74(4):372-379.
18. O'SHAUGHNESSY K M, FU B, DICKERSON C, THURSTON D, BROWN MJ: The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin. Sci. (2000) 99(3):233-238.
19. SOFOWORA CC, DISHY V, MUSZKAT M et al.: A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin. Pharmacol. Ther. (2003) 73(4):366-371.
20. MIALET PEREZ J, RATHZ DA, PETRASHEVSKAYA NN et al.: Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med (2003) 9(10):1300-1305.
21. TERRA SG, HAMILTON KK, PAULY DF et al.: Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogene Genomics (2005) 15(4):227-234.
22. KAYE DM, SMIRK B, WILLIAMS C et al.: Beta2-adrenoceptor genotype influences the responses to carvedilol in patients with congestive heart failure. Pharmacogenetics (2003) 13(7):379-382.
23. DE GROOTE P, HELBECQUE N, LAMBLIN N et al.: Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet. Genomics (2005) 15(3):137-142.
24. TERRA SG, PAULY DF, LEE CR et al.: beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin. Pharmacol. Ther. (2005) 77(3):127-137
25. BORJESSON M, MAGNUSSON Y, HJALMARSON A, ANDERSSON B: A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur. Heart J. (2000) 21(22):1853-1858.
26. MAGNUSSON Y, LEVIN MC, EGGERTSEN R et al.: Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin. Pharmacol. Ther. (2005) 78(3):221-231.
27. WHITE HL, DE BOER RA, MAQBOOL A et al.: An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart Fail. (2003) 5(4):463-468.
28. LIGGETT SB, MAILET-PEREZ J, THANEEMIT-CHEN S et al.: A polymorphism within a conserved beta-1 adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc. Natl. Acad. Sci. [Epub ahead of print].
29. LANFEAR DE, JONES PG, MARSH S et al.: Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 294(12):1526-1533.
30. ZINEH I, BEITELSHEES AL, GAEDIGK A et al.: Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. (2004) 76(6):536-544.
31. CAMBIEN F, ALHENC-GELAS F, HERBETH B et al.: Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am. J. Hum. Genet. (1988) 43(5):774-780.
32. TIRET L, RIGAT B, VISVIKIS S et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. (1992) 51(1):197-205.
33. RIGAT B, HUBERT C, ALHENC-GELAS F et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. (1990) 86(4):1343-1346.
34. OHMICHI N, IWAI N, UCHIDA Y et al.: Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am. J. Hypertens. (1997) 10(8):951-955.
35. STAVROULAKIS GA, MAKRIS TK, KRESPI PG et al.: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc. Drugs Ther. (2000) 14(4):427-432.
36. HARRAP SB, TZOURIO C, CAMBIEN F et al.: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension (2003) 42(3):297-303.
37. KURLAND L, MELHUS H, KARLSSON J et al.: Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am. J. Hypertens. (2002) 15(5):389-393.
38. LI X, DU Y, HUANG X: Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor. J. Cardiovasc. Pharmacol. Ther (2003) 8(1):25-30.
39. ORTLEPP JR, HANRATH P, MEVISSEN V et al.: Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur. J. Pharmacol. (2002) 445(1-2):151-152.
40. YU H, ZHANG Y, LIU G: Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens. Res. (2003) 26(11):881-886.
41. ARNETT DK, DAVIS BR, FORD CE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation (2005) 111(25):3374-3383.
42. MCNAMARA DM, HOLUBKOV R, POSTAVA L et al.: Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J. Am. Coll. Cardiol. (2004) 44(10):2019-2026.
43. CUSI D, BARLASSINA C, AZZANI T et al.: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet (1997) 349(9062):1353-1357.
44. GLORIOSO N, MANUNTA P, FILIGHEDDU F et al.: The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension (1999) 34(4 Pt 1):649-654.
45. SCIARRONE MT, STELLA P, BARLASSINA C et al.: ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension (2003) 41(3):398-403.
46. PSATY BM, SMITH NL, HECKBERT SR et al.: Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA (2002) 287(13):1680-1689.
47. GERHARD T, GONG Y, BEITELSHEES AL et al.: Cardiovascular outcomes, diuretic therapy and the alpha-adducin polymorphism: results for the International Verapamil SR-Trandolapril Study Genetic Substudy (INVEST-GENES) (Abstract). Circulation (2005) 112:II-608.
48. CICOIRA M, ROSSI A, BONAPACE S et al.: Effects of ACE gene insertion/ deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am. J. Med. (2004) 116(10):657-661.
49. LIBBY P: The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. (2005) 46(7):1225-1228.
50. ZINEH I: HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Cardiol. (2005) 1(2):191-206.
51. MANGRAVITE LM, THORN CF, KRAUSS RM: Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. (2006) [Epub ahead of print].
52. CHASMAN DI, POSADA D, SUBRAHMANYAN L et al.: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 291(23):2821-2827.
53. ZINEH I: Genetic polymorphisms and statin therapy. JAMA (2004) 292(11):1302-1303.
54. THOMPSON JF, MAN M, JOHNSON KJ et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. (2005) 5(6):352-358.
55. BALLANTYNE CM, HERD JA, STEIN EA et al.: Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J. Am. Coll. Cardiol. (2000) 36(5):1572-1578.
56. NESTEL P, SIMONS L, BARTER P et al.: A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis (1997) 129(2):231-239.
57. ORDOVAS JM, LOPEZ-MIRANDA J, PEREZ-JIMENEZ F et al.: Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis (1995) 113(2):157-166.
58. GERDES LU, GERDES C, KERVINEN K et al.: The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation (2000) 101(12):1366-1371.
59. GARCIA-OTIN AL, CIVEIRA F, ARISTEGUI R et al.: Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. Eur. J. Clin. Invest. (2002) 32(6):421-428.
60. OJALA JP, HELVE E, EHNHOLM C et al.: Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J. Intern. Med. (1991) 230(5):397-405.
61. PENA R, LAHOZ C, MOSTAZA JM et al.: Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med. (2002) 251(6):518-525.
62. CARMENA R, ROEDERER G, MAILLOUX H, LUSSIER-CACAN S, DAVIGNON J: The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism (1993) 42(7):895-901.
63. MAITLAND-VAN DER ZEE AH, STRICKER BH, KLUNGEL OH et al.: Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics (2003) 13(4):219-223.
64. LEE CR, GOLDSTEIN JA, PIEPER JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics (2002) 12(3):251-263.
65. TAKAHASHI H, ECHIZEN H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. (2001) 40(8):587-603.
66. TAKAHASHI H, KASHIMA T, NOMIZO Y et al.: Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. (1998) 63(5):519-528.
67. DALY AK, AITHAL GP: Genetic regulation of warfarin metabolism and response. Semin. Vasc. Med. (2003) 3(3):231-238.
68. DALY AK, DAY CP, AITHAL GP: CYP2C9 polymorphism and warfarin dose requirements. Br. J. Clin. Pharmacol. (2002) 53(4):408-409.
69. DALY AK, KING BP: Pharmacogenetics of oral anticoagulants. Pharmacogenetics (2003) 13(5):247-252.
70. FURUYA H, FERNANDEZ-SALGUERO P, GREGORY W et al.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics (1995) 5(6):389-392.
71. AITHAL GP, DAY CP, KESTEVEN PJ, DALY AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 353(9154):717-719.
72. VOORA D, EBY C, LINDER MW et al.: Prospective dosing of warfarin based on cytochrome P450 2C9 genotype. Thromb. Haemost. (2005) 93(4):700-705.
73. LI T, CHANG CY, JIN DY et al.: Identification of the gene for vitamin K epoxide reductase. Nature (2004) 427(6974):541-544.
74. ROST S, FREGIN A, IVASKEVICIUS V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency Type 2. Nature (2004) 427(6974):537-541.
75. RIEDER MJ, REINER AP, GAGE BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. (2005) 352(22):2285-2293.
76. SCONCE EA, KHAN TI, WYNNE HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 106(7):2329-2333.
77. D'ANDREA G, D'AMBROSIO RL, DI PERNA P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2005) 105(2):645-649.
78. HARRINGTON DJ, UNDERWOOD S, MORSE C et al.: Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb. Haemost. (2005) 93(1):23-26.
79. PELZ HJ, ROST S, HUNERBERG M et al.: The genetic basis of resistance to anticoagulants in rodents. Genetics (2005) 170(4):1839-1847.
80. WADELIUS M, CHEN LY, DOWNES K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. (2005) 5(4):262-270.
81. YUAN HY, CHEN JJ, LEE MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. (2005) 14(13):1745-1751.
82. VEENSTRA DL, YOU JH, RIEDER MJ et al.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics (2005) 15(10):687-691.
83. AQUILANTE CL, LANGAEE TY, LOPEZ LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. (2006) 79(4):291-302.
84. ZINEH I, GERHARD T, AQUILANTE CL et al.: Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. (2004) 4(6):354-358.
85. WEBSTER A, MARTIN P, LEWIS G, SMART A: Integrating pharmacogenetics into society: in search of a model. Nat. Rev. Genet. (2004) 5(9):663-669.
86. ZINEH I, PEBANCO GD, AQUILANTE CL et al.: Discordance between availability of pharmacogenetic studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann. Pharmacother. (2006) 40(4):639-644.
87. SALERNO RA, LESKO LJ: Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J. (2006) 6(2):78-81.
88. BEITELSHEES AL, ZINEH I, YARANDI HN, PAULY DF, JOHNSON JA: Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J. (2006) 6:174-178.
89. PADMANABHAN S, WALLACE C, MUNROE PB et al.: Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension study. Hypertension (2006) 47(3):603-608.
90. SCHELLEMAN H, STRICKER BH, VERSCHUREN WM et al.: Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J. (2006) 6(1):22-26.